BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA

0.00

Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:

  • PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES

  • PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026

  • PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026

  • PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026

  • PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026

Source text: ID:nGNX2QwHlD

Further company coverage: PVLA.O


((Reuters.Briefs@thomsonreuters.com;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.